Testing A New Experimental Drug To Raise Good Cholesterol Level.
An theoretical poison that raises HDL, or "good," cholesterol seems to have passed an primary block by proving safe in preliminary trials. Although the provisional was primarily designed to look at safety, researchers scheduled to gift the finding Wednesday at the American Heart Association's annual joining in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and eschew LDL, HDL's infelicitous twin, almost in half arab xnxx. "We saw very encouraging reductions in clinical events," said Dr Christopher Cannon, clue maker of the study, which also appears in the Nov 18, 2010 progeny of the New England Journal of Medicine.
A big study to support the results would take four to five years to complete so the numb is still years away from market who is a cardiologist with Brigham and Women's Hospital in Boston. Other experts are intrigued by the findings, but note that the dig into is still in very inopportune stages. "There are a lot of people in the prevention/lipid field that are simultaneously agitated and leery," said Dr Howard Weintraub, clinical principal of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.
Added Dr John C LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: "It's very prelude but it's impressive because the carry on psychedelic out of the barrel of this variety was not a success. This looks like a better drug, but it's not ultimate by any means. Don't take this to the bank".
LaRosa was referring to torcetrapib, which, in the manner of anacetrapib, belongs to the category of drugs known as cholesterol ester transfer protein (CETP) inhibitors. A gargantuan trial on torcetrapib was killed after investigators found an increased peril of death and other cardiovascular outcomes. "I would be more frenetic about anacetrapib if I hadn't seen what happened to its cousin torcetrapib. Torcetrapib raised HDL astoundingly but that was in all respects neutralized by the enlarge in cardiovascular events".
Showing posts with label trial. Show all posts
Showing posts with label trial. Show all posts
Wednesday, April 17, 2019
Thursday, February 21, 2019
Malignant Brain Tumors In Children Will Soon Be Able To Be Curable
Malignant Brain Tumors In Children Will Soon Be Able To Be Curable.
A prelude bone up has found that a targeted remedying for medulloblastoma - the most conventional malignant brain cancer in children - may one age be able to treat drug-resistant forms of the disease. "Less than 5 percent of patients currently pull through medulloblastoma," said Dr Amar Gajjar, create author of the study, which was presented Saturday at the annual meet of the American Society of Clinical Oncology (ASCO) in Chicago medicine. "Most patients by and large die 12 to 18 months after the tumor comes back".
Although this den was designed basically to assess side effects, if the drug moves through the pharmaceutical pipeline, it would be the start targeted drug aimed at a signaling pathway. Chemotherapy is the crucial treatment now. The drug, known as GDC-0449, interrupts the "sonic hedgehog" pathway, which has been implicated in a legions of other cancers; it is interested in 20 percent of cases of children with medulloblastoma.
A prelude bone up has found that a targeted remedying for medulloblastoma - the most conventional malignant brain cancer in children - may one age be able to treat drug-resistant forms of the disease. "Less than 5 percent of patients currently pull through medulloblastoma," said Dr Amar Gajjar, create author of the study, which was presented Saturday at the annual meet of the American Society of Clinical Oncology (ASCO) in Chicago medicine. "Most patients by and large die 12 to 18 months after the tumor comes back".
Although this den was designed basically to assess side effects, if the drug moves through the pharmaceutical pipeline, it would be the start targeted drug aimed at a signaling pathway. Chemotherapy is the crucial treatment now. The drug, known as GDC-0449, interrupts the "sonic hedgehog" pathway, which has been implicated in a legions of other cancers; it is interested in 20 percent of cases of children with medulloblastoma.
Friday, July 14, 2017
PSA Kinetics Is Not A Sufficient Indication For The Treatment Of Prostate Cancer
PSA Kinetics Is Not A Sufficient Indication For The Treatment Of Prostate Cancer.
A mode that urologists had hoped would reckon it tenable to notice men with prostate cancer who need treatment from those who would only difficulty watchful waiting didn't work well, researchers report. The technique, called PSA kinetics, measures changes in the class at which the prostate gland produces a protein called prostate-specific antigen effect. A significant enlargement in PSA kinetics, well-thought-out by the moment during which PSA production doubles or increases at a hasty rate, is supposed to indicate the need for treatment, by radiation treatment or surgery.
PSA kinetics has long been used to measure the effectiveness of treatment. A company of cancer centers have started to use it as a achievable method of distinguishing aggressive cancers that require treatment from those that are so slow-growing that they can safely be socialist alone.
Recent studies indicating that many men with slow-growing prostate cancers bear unnecessary treatment have given exigency to the search for such a tool, especially considering that side effects of treatment can embody incontinence and impotence. But the study indicates that "PSA kinetics doesn't seem to be enough to show you who you should follow and who you should treat," said Dr Ashley E Ross, a urology neighbourhood at the Johns Hopkins University Brady Urological Institute, and restraint architect of a report on the technique published online May 3 in the Journal of Clinical Oncology.
The check in describes the results of PSA kinetics measurements of 290 men with low-grade prostate cancer - the kindly that often doesn't demand care - for an average of 2,9 years. The results of PSA tests were compared with biopsies - web samples - that reasoned the progression of the cancers.
The whirl is part of a study, under supervision of Dr H Ballentine Carter, guide of the division of adult urology at the Brady Urological Institute, that began in 1994. Men in the hassle had PSA tests every six months and biopsies every year.
A mode that urologists had hoped would reckon it tenable to notice men with prostate cancer who need treatment from those who would only difficulty watchful waiting didn't work well, researchers report. The technique, called PSA kinetics, measures changes in the class at which the prostate gland produces a protein called prostate-specific antigen effect. A significant enlargement in PSA kinetics, well-thought-out by the moment during which PSA production doubles or increases at a hasty rate, is supposed to indicate the need for treatment, by radiation treatment or surgery.
PSA kinetics has long been used to measure the effectiveness of treatment. A company of cancer centers have started to use it as a achievable method of distinguishing aggressive cancers that require treatment from those that are so slow-growing that they can safely be socialist alone.
Recent studies indicating that many men with slow-growing prostate cancers bear unnecessary treatment have given exigency to the search for such a tool, especially considering that side effects of treatment can embody incontinence and impotence. But the study indicates that "PSA kinetics doesn't seem to be enough to show you who you should follow and who you should treat," said Dr Ashley E Ross, a urology neighbourhood at the Johns Hopkins University Brady Urological Institute, and restraint architect of a report on the technique published online May 3 in the Journal of Clinical Oncology.
The check in describes the results of PSA kinetics measurements of 290 men with low-grade prostate cancer - the kindly that often doesn't demand care - for an average of 2,9 years. The results of PSA tests were compared with biopsies - web samples - that reasoned the progression of the cancers.
The whirl is part of a study, under supervision of Dr H Ballentine Carter, guide of the division of adult urology at the Brady Urological Institute, that began in 1994. Men in the hassle had PSA tests every six months and biopsies every year.
Friday, October 16, 2015
Prevention Of Cardiovascular Diseases By Dietary Supplements
Prevention Of Cardiovascular Diseases By Dietary Supplements.
Regular doses of the dietary annexe Coenzyme Q10 affront in half the annihilation rate of patients torture from advanced heart failure, in a randomized double-blind trial in May 2013. Researchers also reported a significant shrink in the number of hospitalizations for feeling failure patients being treated with Coenzyme Q10 (CoQ10) tarika. About 14 percent of patients taking the sequel suffered from a notable cardiovascular event that required hospital treatment, compared with 25 percent of patients receiving placebos.
In nitty-gritty failure, the boldness becomes weak and can no longer pump enough oxygen- and nutrient-rich blood throughout the body. Patients often trial fatigue and breathing problems as the magnanimity enlarges and pumps faster in an effort to abut the body's needs. The study is scheduled to be presented Saturday at the annual engagement of the Heart Failure Association of the European Society of Cardiology, in Lisbon, Portugal.
And "CoQ10 is the from the start medication to convalesce survival in chronic heart failure since ACE inhibitors and beta blockers more than a decade ago and should be added to set heart damp squib therapy," lead researcher Svend Aage Mortensen, a professor with the Heart Center at Copenhagen University Hospital, in Denmark, said in a way of life newsflash release. While randomized clinical trails are considered the "gold standard" of studies, because this fresh ponder was presented at a medical meeting, the data and conclusions should be viewed as advance until published in a peer-reviewed journal.
American cardiologists greeted the reported findings with circumspect optimism. "This is a study that is very reassuring but requires replication in a second confirmatory trial," said Dr Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, and a spokesman for the American Heart Association. Fonarow prominent that earlier, smaller trials with Coenzyme Q10 have produced opposite results.
And "Some studies have shown no effect, while other studies have shown some improvement, but not nearly the stimulating paraphernalia displayed in this trial. Coenzyme Q10 occurs unaffectedly in the body. It functions as an electron drayman in cellular mitochondria (the cell's "powerhouse") to remedy alter food to energy. It also is a powerful antioxidant, and has become a stock over-the-counter dietary supplement.
Regular doses of the dietary annexe Coenzyme Q10 affront in half the annihilation rate of patients torture from advanced heart failure, in a randomized double-blind trial in May 2013. Researchers also reported a significant shrink in the number of hospitalizations for feeling failure patients being treated with Coenzyme Q10 (CoQ10) tarika. About 14 percent of patients taking the sequel suffered from a notable cardiovascular event that required hospital treatment, compared with 25 percent of patients receiving placebos.
In nitty-gritty failure, the boldness becomes weak and can no longer pump enough oxygen- and nutrient-rich blood throughout the body. Patients often trial fatigue and breathing problems as the magnanimity enlarges and pumps faster in an effort to abut the body's needs. The study is scheduled to be presented Saturday at the annual engagement of the Heart Failure Association of the European Society of Cardiology, in Lisbon, Portugal.
And "CoQ10 is the from the start medication to convalesce survival in chronic heart failure since ACE inhibitors and beta blockers more than a decade ago and should be added to set heart damp squib therapy," lead researcher Svend Aage Mortensen, a professor with the Heart Center at Copenhagen University Hospital, in Denmark, said in a way of life newsflash release. While randomized clinical trails are considered the "gold standard" of studies, because this fresh ponder was presented at a medical meeting, the data and conclusions should be viewed as advance until published in a peer-reviewed journal.
American cardiologists greeted the reported findings with circumspect optimism. "This is a study that is very reassuring but requires replication in a second confirmatory trial," said Dr Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, and a spokesman for the American Heart Association. Fonarow prominent that earlier, smaller trials with Coenzyme Q10 have produced opposite results.
And "Some studies have shown no effect, while other studies have shown some improvement, but not nearly the stimulating paraphernalia displayed in this trial. Coenzyme Q10 occurs unaffectedly in the body. It functions as an electron drayman in cellular mitochondria (the cell's "powerhouse") to remedy alter food to energy. It also is a powerful antioxidant, and has become a stock over-the-counter dietary supplement.
Subscribe to:
Posts (Atom)